PMID- 31496425
OWN - NLM
STAT- MEDLINE
DCOM- 20200130
LR  - 20200130
IS  - 1607-8454 (Electronic)
IS  - 1024-5332 (Linking)
VI  - 24
IP  - 1
DP  - 2019 Dec
TI  - Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance 
      therapy after induction chemotherapy in patients with indolent non-Hodgkin 
      lymphoma: a single-institution experience.
PG  - 623-630
LID - 10.1080/16078454.2019.1664094 [doi]
AB  - OBJECTIVES: Indolent B-cell non-Hodgkin lymphomas (iNHLs) are considered 
      incurable. Rituximab maintenance and yttrium-90 ibritumomab tiuxetan ((90)Y-IT) 
      consolidation are promising post-remission therapies. However, only one 
      randomized phase II trial has compared their efficacies and adverse effects. 
      Here, we compared the efficacy and safety of (90)Y-IT consolidation and rituximab 
      maintenance in iNHL patients. METHODS: We retrospectively examined 75 iNHL 
      patients with complete or partial response after initial chemotherapy between 
      January 2008 and December 2018. Twenty-seven patients received (90)Y-IT 
      consolidation and 48 received rituximab maintenance (every 2 months for 2 years). 
      Progression-free survival (PFS), overall survival (OS), and time to next 
      treatment (TTNT) were estimated from the start of the treatment, and adverse 
      effects were evaluated. RESULTS: After a median 3.6-year follow-up, the 5-year 
      PFSs of the (90)Y-IT consolidation and rituximab maintenance groups were 75.5% 
      and 82.4%, respectively (log-rank test, p = 0.839), and the 5-year OSs were 100% 
      and 97.8%, respectively (log-rank test, p = 0.465). The corresponding median 
      TTNTs were not reached (log-rank test, p = 0.804). The commonest adverse effect 
      with (90)Y-IT consolidation was hematotoxicity; lower rates and grades of 
      cytopenia were observed in patients who received rituximab maintenance. Secondary 
      malignancies were observed in 1 patient (4%) who received (90)Y-IT consolidation 
      and 2 patients (4.2%) who received rituximab maintenance (Fisher's exact test, 
      p > 0.99). CONCLUSION: (90)Y-IT consolidation and rituximab maintenance were 
      similar with respect to PFS, OS, and TTNT. However, the features and grades of 
      adverse effects significantly differed. Patient-specific characteristics should 
      be considered when deciding post-remission treatments.
FAU - Iino, Masaki
AU  - Iino M
AUID- ORCID: 0000-0002-3471-0890
AD  - Department of Hematology and Hematopoietic Stem Cell Transplantation, Yamanashi 
      Prefectural Central Hospital , Kofu, Yamanashi , Japan.
FAU - Sakamoto, Yuma
AU  - Sakamoto Y
AD  - Department of Hematology and Hematopoietic Stem Cell Transplantation, Yamanashi 
      Prefectural Central Hospital , Kofu, Yamanashi , Japan.
FAU - Sato, Tomoya
AU  - Sato T
AD  - Department of Hematology and Hematopoietic Stem Cell Transplantation, Yamanashi 
      Prefectural Central Hospital , Kofu, Yamanashi , Japan.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hematology
JT  - Hematology (Amsterdam, Netherlands)
JID - 9708388
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Yttrium Radioisotopes)
RN  - 1K8M7UR6O1 (Yttrium-90)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 4Q52C550XK (ibritumomab tiuxetan)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/pharmacology/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Induction Chemotherapy/*methods
MH  - Lymphoma, Non-Hodgkin/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Progression-Free Survival
MH  - Retrospective Studies
MH  - Rituximab/pharmacology/*therapeutic use
MH  - Treatment Outcome
MH  - Yttrium Radioisotopes/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - Post-remission therapy
OT  - adverse event
OT  - consolidation therapy
OT  - conversion rate
OT  - indolent non-Hodgkin lymphoma
OT  - radioimmunotherapy
OT  - rituximab maintenance therapy
OT  - yttrium-90 ibritumomab tiuxetan
EDAT- 2019/09/10 06:00
MHDA- 2020/01/31 06:00
CRDT- 2019/09/10 06:00
PHST- 2019/09/10 06:00 [entrez]
PHST- 2019/09/10 06:00 [pubmed]
PHST- 2020/01/31 06:00 [medline]
AID - 10.1080/16078454.2019.1664094 [doi]
PST - ppublish
SO  - Hematology. 2019 Dec;24(1):623-630. doi: 10.1080/16078454.2019.1664094.